had been diagnosed and who had been referred to our unit for evaluation for radiochemotherapy. Of these 11 tumors, six were glioblastomas multiforme and five were recurrent anaplastic gliomas. There were two women and nine men with a mean mean age of 49 years (range 30-68 years). The cervical SCS electrodes were usually inserted 2 to 3 weeks postsurgery, and the FDG-PET study was performed 1 to 2 weeks later, before the administration of the scheduled radiochemotherapy. For inclusion in the study, patients were required to meet the following criteria: an age of at least 18 years, a Karnofsky Performance Scale score of 60% or better, and a pathological diagnosis of HGG (either its initial appearance or a recurrence). Excluded were patients receiving oral anticoagulant treatment. Fully informed consent was obtained from all patients. The study protocol for the evaluation of, and adjuvant treatment with, a cervical SCS device was approved by the institutional ethics committee, and the elective use of PET was approved by our health department. This study was a nonrandomized prospective one in which each patient was his or her own control. The sample size was established according to our previous data regarding the measurement of tumor blood flow by using SPECT. 2 Additional patient details are summarized in Table 1.
Cervical SCS
Cervical SCS was performed using a commercially available system (Medtronic, Inc., Minneapolis, MN) with a 1.27-mm-diameter tetrapolar electrode percutaneously inserted on the posterior surface of the spinal cord at C2-4, in the epidural space and slightly displaced toward the tumorous side. The electrode was connected to a subcutaneous impulse generator that delivered an adjustable range of pulse width, intensity, and frequency of stimulation. These parameters were individually adjusted for each patient to produce mild paresthesia in the upper limbs: intensity, 1 to 3 V; pulse width, 200 sec; pulse rate, 80 to 100 Hz. Following electrode insertion, the cervical SCS device was maintained in the off position until the PET study.
Positron Emission Tomography Studies
We used a C-PET 250 device (Philips-ADAC-UGM, Philadelphia, PA) to measure the levels of FDG. Patients were evaluated twice on the same day: in basal conditions and following SCS. The baseline FDG-PET study was conducted following the intravenous injection of FDG (1 MBq/ kg body weight) with the patient supine and calm in a dimly lit room. Patients were advised to fast for a minimum of 6 hours before the exploratory study. Images were acquired 45 minutes after the injection of FDG by using a C-PET camera equipped with six curved sodium iodide detector crystals arranged in full ring array. Attenuation correction was performed with a postinjection quasisimultaneous transmission scan using a 137 Cs rotating source. The second FDG-PET study commenced approximately 2 hours later. Patients were instructed to switch on the SCS device approximately 10 minutes before the intravenous injection of the second FDG dose (2 MBq/kg body weight) and to keep it on for the next 20 to 30 minutes; thus, stimulation was turned off for approximately 20 minutes after the second injection and before the second FDG-PET scan. Images were acquired with exactly the same protocol as that used to ob- (increase): (SUV max post-SCS Ϫ SUV max pre-SCS) ϫ 100/SUV max pre-SCS. § Relapsed patients. Case 1: local progression after previous subtotal resection and radiotherapy; diagnosis by MR imaging and FDG-PET. Case 2: previous biopsy and radiotherapy for Grade I oligodendroglioma; recurred as Grade III oligodendroglioma with macroscopic resection but higher uptake on PET. Case 3: local recurrence with component of Grade III astrocytoma after two previous complete resections for gemistocytic astrocytoma. Case 7: two meningeal implants after resection of local recurrence (with previous surgery and radiotherapy); implants did not undergo biopsy and diagnosis was made using MR imaging and FDG-PET. Case 8: recurrence after complete surgery and radiotherapy; FDG-PET assessment was performed before confirmatory surgery. Case 11: local recurrence of Grade III mixed oligodendroglioma (with previous radiotherapy); recurrence did not undergo biopsy and diagnosis was made using MR imaging and FDG-PET.
|| Surgery was not performed before PET assessment.
tain the first scan, including reconstruction with an iterative algorithm (slice thickness 2 mm), reorientation parallel to the bases of frontal and occipital cerebral lobes, and display in transversal, sagittal, and coronal views. Semiquantitative measurements of glucose uptake and metabolism in the brain were evaluated. The SUV max were calculated in both PET studies in regions of interest: tumor and peritumoral areas defined with visual reference to a pretreatment computerized tomography scan and/or MR image. The SUV max were estimated as a semiquantitative measurement calculated with the following equation: (Q max ϫ W)/Q inj , where Q max is the maximal FDG uptake in the tumor or peritumoral area (MBq/L), W represents body weight (kg), and Q inj is the activity of the dose of injected FDG. Additionally, in applying this procedure, the maximal residual activity of the first FDG dose, which could potentially contribute to the increase in activity on the second scan, was calculated for each patient. The PET studies pre-and post-SCS were performed by the same three specialists in Nuclear Medicine who were not blinded to patient data.
Statistical Analysis
The SPSS (version 7.0 for Windows; SPSS Ibérica, Madrid, Spain) was used throughout. The two-tailed paired t-test was applied to compare values between different areas pre-and post-SCS. Measured data are expressed as the means Ϯ standard deviations. The percentage of increase is expressed as the means and 95% CIs. All probability values of 0.05 or less were considered statistically significant.
Results
All 11 patients were evaluable for this PET study. There was a clear increase in glucose metabolism in the tumor and peritumoral areas in eight (73%) of 11 patients. In the tumors, SUV max pre-and post-SCS were 6.75 Ϯ 1.3 and 9.65 Ϯ 2.4, respectively (p = 0.035), representing an increase of 43% (95% CI 4-82%). In peritumoral areas, the SUV max pre-and post-SCS were 4.53 Ϯ 0.68 and 6.27 Ϯ 0.88, respectively (p = 0.001), representing an increase of 38% (95% CI 19-58%). Before SCS, SUV max were higher in the tumor than in peritumoral areas (p = 0.048; Fig. 1 ). Representative images are featured in Fig. 2 . Table 1 shows the individual values of SUV max pre-and post-SCS.
The estimated potential maximal residual activity of the first FDG dose contributing to activity on the second scan was 18.5 Ϯ 1% or less.
We found no significant difference in glucose metabolism or in the percentage of modification in relation to the tumor grade or tumor status as a new or recurrent lesion. Individual PET measurement data are presented in Table 1 .
Discussion
Tumor cell metabolism depends on the glycolytic pathway, which is not oxygen dependent but essentially relies
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Brain tumor metabolism modification by cervical SCS on glucose supply, which, in turn, is dependent on blood flow. 22 Hence, in the present study, the increase in glucose uptake in the tumor and peritumoral areas after cervical SCS should be associated with increased glucose availability caused by an increase in blood flow. This result is in agreement with data from our previous studies of cervical SCS in patients with brain tumors, showing blood flow increases in tumorous middle cerebral arteries (as assessed using transcranial Doppler ultrasonography) as well as in tumors (as assessed using SPECT). 2 Our hypothesis is further supported by a preliminary report of PET measurements in a vegetative noncancerous patient in whom the pattern of increase in cerebral blood flow was almost the same as that in glucose uptake. 12 There are several hypotheses regarding the mechanisms responsible for the cervical SCS-induced increase in tumor blood flow and, secondarily, glucose metabolism. The segmental liberation of vasoactive substances and the activation of vasomotor centers in the brainstem 16, 17, 20 as well as a sympatholytic effect 10, 15, 16, 20 have been described. In addition, preexisting host vessels incorporated into the lesion 18 could explain the tumor blood flow response to cervical SCS, whereas defective self-regulatory mechanisms in tumor vessels 22 would not preclude regional blood flow increases in response to SCS. Indeed, nitric oxide mediation of tumor PO 2 increases after electrical nerve stimulation has been reported. 9 The observed capacity of cervical SCS to increase glucose metabolism in tumors and peritumoral areas is of considerable clinical interest. This modification could result in the recruitment of tumor cells into a more active metabolic state, making them potentially more sensitive to chemotherapy and radiotherapy. This hypothesis is supported by the significant correlation between a better response to temozolomide and a higher metabolic rate of glucose (as measured using PET). 1 Metabolism in HGGs is evidenced by energy production from glycolysis and subsequent lactate production and release, together with the induction of interstitial acidosis. The potential effect of cervical SCS on these parameters merits specific consideration. Lactate accumulation has been related to higher cell migration in peritumoral areas 19 and adverse prognosis in HGGs. 21 Acidosis can, independently of hypoxia, upregulate vascular endothelial growth factor transcription and encourage neoangiogenesis in brain tumors, thus enhancing tumor progression. 5 Also, a shift of cells to the G 1 and G 0 phases in the cell cycle with further resistance to radiochemotherapy could be induced by interstitial acidosis as well as an enhancement of metastases formation. 22 Increased glucose metabolism resulting from cervical SCS administration could lead to an adverse increase in lactate production and acidosis. However, tumor acidosis develops mainly as a result of inadequate drainage through tumor tissue perfusion. 22 Hence, we hypothesized that an increased locoregional blood flow induced by cervical SCS could decrease extracellular acidosis and intracellular lactate accumulation. The modification of both biological parameters could theoretically improve the efficacy of radiotherapy and/or chemotherapy agents. Additionally, a decrease in extracellular acidosis (that is, an increase in pH) could facilitate lactate elimination in tumor tissue with a further decrease in tumor acidosis and, as such, could enhance the activity of drugs such as temozolomide, which requires an alkaline pH to be hydrolyzed to the active metabolite methyl-triazen-imidazol-4-carboxamide.
A marked deleterious effect of cervical SCS in healthy tissues is not expected, as supported by our previous data. 2, 3 Radiotherapy is delivered principally in the tumor and peritumoral areas. Conversely, a potential increase in blood flow and oxygenation in healthy tissues (which are usually well oxygenated) would have very minor effects on radiosensitivity, which occurs at the upper end of the asymptotic curve of radiosensitivity and oxygenation, as we have previously described. Additionally, the main toxicity for chemotherapy (as well as for temozolomide) is the hematological toxicity, which would not be increased by the local effect of cervical SCS.
Although several authors have described the adverse implications of tumor ischemia/hypoxia and results of a metaanalysis have shown that modification of tumor ischemia/ hypoxia does not significantly increase tumor dissemination, 13 additional studies are needed to establish the implications of tumor microenvironment modification by cervical SCS and to confirm SCS as an adjuvant in the treatment of these tumors.
Finally, we must note that the estimated potential maximal residual activity of the first FDG dose carryover to the second scan was 18.5% or less, which implies that the measured 40% increase in tumor metabolism by cervical SCS (43% in the tumor and 38% in peritumoral areas) must be adjusted for this potential carryover. Probably, a more realistic estimate would be approximately 20%. The percentage of modification described in the present FDG-PET study is similar to that revealed in our previous studies with transcranial Doppler ultrasonography and SPECT. 2 Furthermore, the percentage of patients with a clear increase in glucose metabolism (taking into account the potential maximal residual activity) is similar to the percentage of patients with a clear increase observed in our previous study of tumor blood flow assessment using SPECT. 
Conclusions
To the best of our knowledge, this is the first report of data proving an increase in glucose uptake in brain tumors following cervical SCS. Data in the present study support our previous findings on the potential locoregional blood flow increase in brain tumors after cervical SCS. This result allows the possibility of using cervical SCS to modify the metabolism and microenvironment of the tumor in the course of radiochemotherapy for the treatment of HGGs. Additional research is required to confirm the clinical benefits of using this approach.
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